Search results
Vanguard Health Care Fund's Strategic Moves in Q1 2024: A Focus on Pfizer Inc
GuruFocus.com via Yahoo Finance· 5 days agoThe top holdings were 8.97% in Eli Lilly and Co (NYSE:LLY), 6.45% in UnitedHealth Group Inc...
Pharma R&D productivity seen improving for the first time in years
Seeking Alpha· 4 days agoDiscover the latest findings on the return on investment from pharmaceutical...
IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
WKBN 27 Youngstown· 2 days agoASCO 2024 oral presentation of darovasertib neoadjuvant UM Phase 2 investigator-sponsored trial on June 3rd, and targeting neoadjuvant UM update in over 30 patients from Phase 2 company-sponsored ...
Sentynl Therapeutics Announces Global Acquisition of Zokinvy® (Lonafarnib) for Treatment of...
WKBN 27 Youngstown· 5 days agoSentynl, a Zydus Group company, receives worldwide proprietary rights to Zokinvy, adding to portfolio of biopharmaceuticals for rare and ultra-rare diseases Zokinvy is approved in the U.S. ( ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 2 days agoNew York, USA, May 06, 2024 (GLOBE NEWSWIRE) -- Global Liver Disease Therapeutics Market to Grow Rapidly by 2030, Examines DelveInsight | Key Players in the Market - AbbVie, GSK, F.Hoffmann-La Roche, Bristol-Myers Squibb Company, Abbott, Gilead